TP n | FP n | TN n | FN n | Concordance % (95% CI) | Sensitivity % (95% CI) | Specificity % (95% CI) | PPV % (95% CI) | NPV % (95% CI) | |
---|---|---|---|---|---|---|---|---|---|
All cases (n = 101) | |||||||||
Virtopsy | 86 | 7 | 5 | 3 | 90.1 (82.7 to 94.5) | 96.6 (90.6 to 98.8) | 41.7 (19.3 to 68.0) | 92.5 (85.3 to 96.3) | 62.5 (30.6 to 86.3) |
Clinical evaluation | 59 | 12 | 6 | 24 | 64.4 (54.6 to 73.0) | 71.1 (60.6 to 79.7) | 33.3 (16.3 to 56.3) | 83.1 (72.7 to 90.1) | 20.0 (9.5 to 37.3) |
Foetuses ≤ 24 weeks (n = 58) | |||||||||
Virtopsy | 50 | 2 | 4 | 2 | 93.1 (83.6 to 97.3) | 96.2 (87.0 to 98.9) | 66.7 (30.0 to 90.3) | 96.2 (87.0 to 98.9) | 66.7 (30.0 to 90.3) |
Clinical evaluation | 36 | 7 | 4 | 11 | 69.0 (56.2 to 79.4) | 76.6 (62.8 to 86.4) | 36.4 (15.2 to 64.6) | 83.7 (70.0 to 91.9) | 26.7 (10.9 to 52.0) |
Foetuses > 24 weeks (n = 26) | |||||||||
Virtopsy | 23 | 1 | 1 | 1 | 92.3 (75.9 to 97.9) | 95.8 (79.8 to 99.3) | 50.0 (9.5 to 90.5) | 95.8 (79.8 to 99.3) | 50.0 (9.5 to 90.5) |
Clinical evaluation | 12 | 3 | 1 | 10 | 50.0 (32.1 to 67.9) | 54.5 (34.7 to 73.1) | 25.0 (4.6 to 69.9) | 80.0 (54.8 to 93.0) | 9.1 (1.6 to 37.7) |
Infants (n = 17) | |||||||||
Virtopsy | 13 | 4 | 0 | 0 | 76.5 (52.7 to 90.4) | 100.0 (77.2 to 100.0) | 0.0 (0.0 to 49.0) | 76.5 (52.7 to 90.4) | NaN |
Clinical evaluation | 11 | 2 | 1 | 3 | 70.6 (46.9 to 86.7) | 78.6 (52.4 to 92.4) | 33.3 (6.1 to 79.2) | 84.6 (57.8 to 95.7) | 25.0 (4.6 to 69.9) |
Cases with unclear cause of death after clinical evaluation (n = 30) | |||||||||
Virtopsy | 18 | 4 | 5 | 3 | 76.7 (59.1 to 88.2) | 85.7 (65.4 to 95.0) | 55.6 (26.7 to 81.1) | 81.8 (61.5 to 92.7) | 62.5 (30.6 to 86.3) |
Cases with infective deaths (n = 20) | |||||||||
Virtopsy | 17 | 3 | 0 | 0 | 85.0 (64.0 to 94.8) | 100.0 (81.6 to 100.0) | 0.0 (0.0 to 53.1) | 85.0 (64.0 to 94.8) | NaN |
Clinical evaluation | 7 | 7 | 6 | 0 | 35.0 (18.1 to 56.7) | 53.8 (29.1 to 76.8) | 0.0 (0.0 to 35.4) | 50.0 (26.8 to 73.2) | 0.0 (0.0 to 39.0) |